Kappel, Rhineland-Palatinate



Traditionally, Heidelberg's philosophers and university professors would walk and talk along the pathway. In , a lightning bolt destroyed other palace buildings during reconstruction, causing the work to be discontinued. Modern Heidelberg can trace its roots to this 12th-century monastery. It was rebuilt after the French set fire to it in during the War of the Palatinian Succession.

Quick Links


Help make pornstars easier to find on YouPorn by telling us who is in this video. Comment contains invalid characters. Comment cannot be longer than characters. Name contains invalid characters. Name cannot be longer than characters. Thank you for submitting your comment! All comments are moderated and may take up to 24 hours to be posted. Subscribe to your favorite pornstars, channels, and collections. Von zwei Kerlen heftig doppelpenetriert.

Please send any copyright reports to: Only one flag request every ten seconds is allowed. Please try again later. Ads by Traffic Junky. Autoplay Next Video On Off. BFFs Site Ranking 76 th. References [1] American Society of Clinical Oncology.

Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology, December ; 1; Melanie Rolli as Chief Medical Officer. Melanie Rolli brings more than a decade of industry experience and senior responsibilities in global development, medical affairs and patient safety. Download a PDF version of the press release here English. PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, and Pierre Fabre, the second largest private French pharmaceutical group announced today that they have signed a collaboration agreement for the Following the first stage of the collaboration, Pierre Fabre will have the option to enter into exclusive negotiations to license global rights for the program in selected skin cancer conditions.

Terms and conditions of the collaboration were undisclosed. Pierre Fabre is strategically positioned in both oncology and dermatology from discovery all the way through commercialization with multiple products at various stages of development and already launched on the market. Combining our capabilities will accelerate the drug discovery process and bringing forward transformative therapies for patients.

PCNSL is a very rare and aggressive form of lymphoma involving brain and its linings, eyes or spinal cord. The designation provides the company several benefits and incentives, including assistance with clinical study design and drug development, tax credits for qualified clinical trials costs, exemptions from certain FDA application fees, as well as a seven-year period of market exclusivity upon regulatory product approval.

Unlike most of its competitors, PQR crosses the blood-brain barrier, expanding its use to malignant diseases involving the brain. Preclinical and Phase 1 studies have shown PQR to have a favorable safety, tolerability and pharmacokinetic profile.

In addition, PQR has shown both preclinical activity in various tumor models and clinical activity in Phase 1 and 2 studies. A significant number of HER2-negative breast cancer patients are expected to have activated PI3K, de novo or induced by prior chemotherapy administration. PQR is currently engaged in multiple Phase 1 and Phase 2 studies as a single agent and has shown promising activity. The initial Phase 1 dose-escalation part of the study will assess the safety and tolerability of PQR combined with eribulin in patients with locally advanced or metastatic HER2-negative and triple-negative breast cancer.

The primary objective of this part of the study is to evaluate the efficacy of the PQR in combination with eribulin. Eribulin is the first in the halichondrin class, microtubule dynamics inhibitors with a novel mechanism of action. Structurally eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai.

Eribulin is believed to work by inhibiting the growth phase of microtubule dynamics which prevents cell division. Eribulin remains the only single agent chemotherapy to significantly improve overall survival in women with advanced breast cancer after anthracycline and taxane treatment.

Eisai is committed to oncology to address the unmet medical needs of patients and their families. To read the full press release, please visit the ESMO website. This round was backed by several existing investors, including Versant Ventures, as well as new, private investors. In addition, the new funding will support the preclinical safety and first clinical studies for one of its follow-up compounds.

Two out of three people are now living at least five years after their cancer has been diagnosed. PIQUR targets both PI3K phosphoinositide 3-kinase and mTOR mammalian target of rapamycin , two key signaling molecules that are vital to several essential biological processes involved in malignant disease, such as cell growth, proliferation, survival and metastasis, making them attractive targets in cancer therapy.

Unlike most of its competitors, PQR crosses the blood-brain barrier, expanding its use to oncologic as well as hematologic malignant diseases involving the brain. PIQUR has a secured patent scope protecting many chemical compounds.

The pharmaceutical company wins the SEF. The three winning companies were chosen by a high-calibre jury in a three-stage judging process. What most impressed the jury about PIQUR is the speed in bringing together an interdisciplinary and very competent team of experts from industry and academia. Furthermore PIQUR attracted many renowned Swiss and International investors as the company succeeded in reaching key clinical milestones earlier than expected.

This start-up prize also spurs us on to channel our commitment and energy into further developing our product pipeline. Our goal is to put ourselves in a position to offer another treatment option to as many cancer patients as possible soon. The preliminary jury analysed the dossiers submitted by the companies based on the criteria specified by the judging process, which is certified by the Swiss Association for Quality Management Systems SQS.

The jurors then short-listed 15 start-ups, which received an on-site visit from a group of 15 experts. The aim of the Swiss Economic Award is to foster an entrepreneurial spirit and help young entrepreneurs make their way in society. The competition is open to all companies that have been established for no more than six years and are based in Switzerland.

The winners receive CHF 75, in prize money and a comprehensive package of rewards. Further information is available at www.

Two out of three people are now living for at least five years after their cancer has been diagnosed. PIQUR focuses specifically on PI3K phosphoinositide 3-kinase and mTOR mammalian target of rapamycin , key signalling molecules that play a vital role in various biological processes involved in malignant diseases, such as cell proliferation, survival and metastasis, making them attractive prospects for cancer therapy.

Unlike most of its competitors, PQR crosses the blood-brain barrier, expanding its use beyond solid tumors and lymphomas and into brain cancers. Study confirms that PQR is well tolerated and shows promising signs of clinical antitumor activity Please find PDF versions of the release here German and here English.

Study confirms that PQR is well tolerated and shows promising signs of clinical antitumor activity. Preclinical studies demonstrated that PQR is a highly selective kinase inhibitor, penetrating blood-brain barrier with potent in vitro as well as in vivo antitumor activity. The results from the first-in-man Phase 1 trial indicate that PQR is safe and well tolerated with expected pharmacokinetic profile, pharmacodynamic effect as well as clinical activity. In total, 28 patients with advanced solid tumors were treated in cohorts of escalating PQR doses.

The maximum tolerated dose MTD of PQR was determined to be 80 mg administered at continuous once-daily dosing schedule. Pharmacokinetic data indicate fast absorption of PQR as well as dose proportionality.

S Hall A, Poster Board ]. PIQUR targets both PI3K phosphoinositide 3-kinase and mTOR mammalian target of rapamycin , two key signaling molecules that are vital to several essential biological processes involved in malignant disease, such as cell proliferation, survival and metastasis, making them attractive targets in cancer therapy.

Initial clinical results confirm that PQR is well tolerated and shows first signs of clinical antitumor activity PIQUR Therapeutics AG today announced that the company and its academic collaborators Initial clinical results confirm that PQR is well tolerated and shows first signs of clinical antitumor activity.

Initial results from the first-in-man phase 1 trial indicate that PQR is safe and well-tolerated with no significant side effects. PIQUR targets both PI3K phosphoinositide 3-kinase and mTOR mammalian target of rapamycin , two key signaling molecules that are vital to several essential biological processes, such as cell proliferation, survival and metastasis, making inhibition of the target attractive for cancer therapy.

PIQUR has successfully concluded the first-in-man phase 1 study in Europe; the maximum tolerated dose MTD was determined and the results indicated first evidence of clinical antitumor activity. The full results of the phase 1 trial are anticipated in the second quarter of after completion of the ongoing expansion study in USA.

One of the laureates is Prof. Hall from the Biozentrum of the University of Basel. The award recognizes his discovery of the protein kinase TOR Target of Rapamycin and its role as a key regulator of cell growth.

With this prize, endowed with CAD ,, the Gairdner Foundation each year recognizes research scientists for their groundbreaking discoveries in the medical sciences. The series of successes of Michael N. Hall, professor of biochemistry at the Biozentrum of the University of Basel, continues.

In , he received the Louis-Jeantet Prize, the most prestigious award for European medical science. Three years later he was awarded the highest Swiss distinction, the Marcel Benoist Prize.

This year, the Gairdner Foundation is honoring five scientists for their medically significant discoveries with its award endowed with the equivalent of approximately CHF 75, For almost 30 years, Michael N. Hall has been working at the Biozentrum. The discovery of TOR was not only a major milestone in basic research but also proved to be of clinical relevance.

With the prize from the Gairdner Foundation, Hall once again receives one of the highest acknowledgments for his excellent and comprehensive research, reaching from the discovery to the elucidation of the importance of TOR for cell growth and metabolism and further to providing answers to medical issues.

The formal prize presentation will take place on 29 October , at a ceremony in Toronto, Canada. The Canada Gairdner Awards were created in to recognize and reward the achievements of researchers whose work contributes significantly to improving the quality of human life. The prize is awarded annually and the winners are selected by an international committee. During its history, the prize has also been previously awarded to two scientists from the Biozentrum: In to Prof.

Walter Gehring and in to Prof. On 7 November , at the Congress Centre On 7 November , at the Congress Centre of the Basel Trade Fair, six finalists were presented and recognized for their work in front of an audience of guests.

PIQUR stood out from some 60 competitors all vying for the award. At the same time, the award gives us the incentive to continue the so far successful development of our drug PQR with passion and determination.

The pharmaceutical company focused on the discovery and development of novel, small molecules for the treatment of cancer, has closed a Series A extension round of CHF 18 million USD 20M. Versant Ventures led the extension round, which also included new as well as existing private shareholders. Versant Ventures, specializing in life sciences investments, has more than USD 1. Versant Ventures has recently established an industry-leading biotech-focused team in Basel, Switzerland.

Prior to that he was the Head of the Medical Science Department of Roche Pharmaceuticals and oversaw the development and the registration of a large number of key oncology drugs. Currently, he serves on the Board of Novira Therapeutics and on scientific advisory boards of a number of academic institutions and biotechs. We plan to use the funds to advance development of our lead compound PQR to reach Phase II and deliver proof-of-concept in the clinic, as well as the discovery of additional drug candidates for oncology and non-oncology indications.

PIQUR targets both PI3K phosphoinositide 3-kinase and mTOR mammalian target of rapamycin , two key signaling molecules that are vital to several essential biological processes, such as cell proliferation and survival, making inhibition of the target attractive for cancer therapy.

About Versant Ventures Versant Ventures is a leading venture capital firm that specializes in investments in innovative biopharmaceuticals, medical devices and other life science opportunities.

Founded in , the firm consists of an experienced team of managing directors committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life. In addition to an industry-leading biotech-focused team in Basel, Switzerland, Versant is present in San Francisco and two locations in Canada. The private placement was rapidly oversubscribed.

Subscribers include existing shareholders as well as new investors from the life science industry. In particular, we successfully attracted further distinguished individuals from the life science industry as investors. The successful round of funding has encouraged us in our determination to continue pursuing our corporate strategy.

The funds that have been procured secure the cost of the first clinical studies with our lead compound PQR This study will assess the safety in cancer patients, and will help determine the ideal dosage.

Also of crucial importance for the future development of the company is the broadening of the license agreement with the University of Basel. The license agreement with the University of Basel was previously limited to the field of cancer, and has now been extended to a broad range of promising clinical indications. Bernd Giese, Chairman of the Board of Directors. Hall, Professor of Biochemistry at the Biozentrum of This award honors Hall for his discovery of target of rapamycin TOR , a central regulator of cell growth and metabolism.

This is the first time that this prize, endowed with three million dollars, has been granted to a scientist in Switzerland. Among them was Prof. The prize is awarded for outstanding research achievements aimed at curing intractable diseases and extending human life. The Breakthrough Prize was granted this year for the second time and is endowed with three million dollars for each awardee. In TOR, Hall found a key protein in cellular communication, which though producing a pharmacological blockade can contain the uncontrolled cell division that is typical for cancer.

Insights into TOR signaling pathways and their dysregulation in disease may provide new therapeutic strategies for a wide range of diseases. Hall has published his research findings in over scientific articles and currently leads a team of 12 researchers.

He is a member of several advisory and editorial boards and professional societies such as the American Association for the Advancement of Science AAAS. Hall is a SystemsX. Hall is a Swiss-American dual citizen and lives with his family in Basel. Basel, Switzerland — PIQUR Therapeutics AG, focused on the discovery and development of innovative anti-cancer drugs, announces that is has successfully closed a third seed financing round.

The private placement was oversubscribed in a very short time frame and included new investors from the life science sector as well as existing shareholders. The financing gives us the means to start with the clinical development program and to bring our lead compound PQR one step closer to become an excellent targeted cancer drug. By this appointment the Company broadens the expertise of its Board in the field of management, finance and investor relations.

Given the relatively small number of effective cancer treatments available today, there is an unmet medical need for new therapeutic approaches. One in every two men and one in every three women, living in the developed world, will develop cancer at some stage in their lives. Our compound has a benefit to risk ratio that is anticipated to be superior to other PI3K inhibitor front-runners.